The Effect of Metformin Usage in Patients With Metastatic Colorectal Cancer Receiving First-line Systemic Therapy
Metformin usage in patients with mCRC receiving systemic therapy may improve progression-free survival but does not significantly affect overall survival. This result outlines the potential of metformin in mCRC treatment, especially in enhancing the progression-free survival. Further studies are needed to confirm the role of metformin in systemic treatment of mCRC.
Authors
- Yasemin Geriş
- Güngör Utkan (ORCID: https://orcid.org/0000-0001-8018-6017)
- Merih Yalçıner
- Efe Cem Erdat (ORCID: https://orcid.org/0000-0002-1250-1297)
Institutions
- Ankara University (TR)
Publication Details
- Journal
- In Vivo
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/invivo.14032
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00